Showing results (431-440 of 554) with videos related to

Sort By:
Pageof 56
Journal of Immunotherapy (Hagerstown, Md. : 1997)|June 21, 2002
Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological TherapyUlrich Keilholz, Jeffrey Weber, James H Finke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2019
Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition-A Pooled Analysis of Patients With Advanced MelanomaMeredith M Regan, Lillian Werner, Sumati Rao, et al.
Journal for Immunotherapy of Cancer|January 31, 2018
Clinical activity of nivolumab in patients with non-clear cell renal cell carcinomaVadim S Koshkin, Pedro C Barata, Tian Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 1, 1997
Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignanciesM B Atkins, M J Robertson, M Gordon, et al.
Gastrointestinal Endoscopy|December 9, 2014
Electronic chromoendoscopy, Michael A Manfredi, Barham K Abu Dayyeh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2024
A Pooled Analysis of Treatment-Free Survival in Advanced Renal Cell CarcinomaElaine Chang, Jiaxi Zhou, Chi Song, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 14, 2016
Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients With Metastatic Clear Cell Renal Cell CarcinomaAndre P Fay, Guillermo de Velasco, Thai H Ho, et al.
Cancers|March 25, 2022
Transcriptional Profiling of Malignant Melanoma Reveals Novel and Potentially Targetable Gene FusionsSourat Darabi, Andrew Elliott, David R Braxton, et al.
Molecular Cancer Research : MCR|May 29, 2012
State of the science: an update on renal cell carcinomaEric Jonasch, P Andrew Futreal, Ian J Davis, et al.
Journal for Immunotherapy of Cancer|April 11, 2024
Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A)Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, et al.
Pageof 56